Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Operating Leases (2023 - 2025)

Kura Oncology (KURA) has disclosed Operating Leases for 3 consecutive years, with $9.5 million as the latest value for Q4 2025.

  • Quarterly Operating Leases rose 82.45% to $9.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.5 million through Dec 2025, up 82.45% year-over-year, with the annual reading at $9.5 million for FY2025, 82.45% up from the prior year.
  • Operating Leases for Q4 2025 was $9.5 million at Kura Oncology, up from $8.4 million in the prior quarter.
  • The five-year high for Operating Leases was $9.5 million in Q4 2025, with the low at $1.5 million in Q2 2023.
  • Average Operating Leases over 3 years is $6.1 million, with a median of $6.3 million recorded in 2023.
  • Peak annual rise in Operating Leases hit 301.58% in 2024, while the deepest fall reached 18.42% in 2024.
  • Over 3 years, Operating Leases stood at $6.4 million in 2023, then fell by 18.42% to $5.2 million in 2024, then soared by 82.45% to $9.5 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $9.5 million, $8.4 million, and $8.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.